Okogen Inc., a biotechnology company developing antiviral therapeutics, announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. This strategic move strengthens the company's lead ophthalmic program while establishing a foundation for expansion into additional antiviral indications. The acquisition expands Okogen's development pipeline beyond ocular infections into focused therapeutic areas including eyecare, systemic infectious disease, dermatology, and medical countermeasures for high-consequence pathogens such as filoviruses.
The company prioritizes rapid advancement of its lead ranpirnase program, OKG-0303, an investigational therapy for acute infectious conjunctivitis. This development addresses a disease area where treatment remains fragmented with no single therapy addressing both viral and bacterial causes. The acquisition positions Okogen to potentially offer a more comprehensive solution in this therapeutic space.
Ranpirnase represents a differentiated approach to antiviral development through its host-directed mechanism. As a ribonuclease enzyme, it disrupts viral replication inside infected cells by degrading intracellular RNA involved in protein synthesis, creating a translational bottleneck that limits production of viral proteins required for replication. This mechanism targets a host process essential to viral propagation, potentially reducing susceptibility to resistance observed with traditional direct-acting antivirals. Research supporting this mechanism has been documented in publications such as https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077210/.
Beyond ophthalmology, Okogen advances ranpirnase as a potential antiviral medical countermeasure and engages with U.S. and international government agencies to evaluate its role against high-consequence pathogens such as Marburg and Sudan viruses. The company also progresses parallel research in respiratory viruses including influenza and RSV. The therapeutic molecule has been evaluated in clinical trials involving more than 1,000 patients, generating substantial safety and translational data supporting continued development across multiple indications.
The acquisition establishes core development pillars spanning ophthalmology, respiratory viruses, medical countermeasures for high-consequence pathogens, and dermatologic viral diseases. This expansion comes at a time when antiviral development faces increasing challenges with resistance to traditional therapies. The ranpirnase platform's broad-spectrum potential across multiple therapeutic areas represents a significant strategic development in antiviral research, particularly given the growing need for medical countermeasures against emerging pathogens. The transaction positions Okogen to address multiple unmet medical needs across different disease categories with a single therapeutic platform.
